sickle cell disease

News

Agios shares slump on sickle cell disease data

Shares in Agios lost nearly half their value after it posted mixed clinical results from a phase 3 trial of its sickle cell disease therapy mitapivat.

News

Pfizer suffers another hit to its GBT sickle cell portfolio

Pfizer's $5.4 billion takeover of Global Blood Therapeutics three years ago is starting to look like a poor deal.

Digital

Enhancing rare disease trials: eCOA technology’s impact on s...

Sickle cell disease (SCD) affects an estimated 20 million people worldwide.

News

Sickle cell gene therapy Casgevy finally cleared for NHS use

Vertex's gene-editing therapy for sickle cell disease, Casgevy, has been given the nod for use by the NHS in England after an earlier rejection.

News

Editas axes two-thirds of its staff, including its CMO

Editas Medicine ends development of its gene-editing therapy for thalassaemia and sickle cell, shedding 65% of staff and narrowing its R&D focus.

News

Beam Therapeutics' chief executive John Evans

Beam points to positive data with key base editing asset

It has been around a year since Beam Therapeutics slashed its headcount and R&D programmes to focus mainly on a sickle cell disease candidate – and the biotech has now revealed the firs

Agios shares slump on sickle cell disease data

Pfizer suffers another hit to its GBT sickle cell portfolio

Enhancing rare disease trials: eCOA technology’s impact on s...

Sickle cell gene therapy Casgevy finally cleared for NHS use

Editas axes two-thirds of its staff, including its CMO

Beam points to positive data with key base editing asset

FDA approves higher Wegovy dose via 4th priority voucher

Using AI-driven synthetic personas to take your insights fur...

sickle cell disease

Editor's Picks